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We developed a computational method (ABSOLUTE) that infers tumor purity and malignant cell 
ploidy directly from analysis of somatic DNA alterations. ABSOLUTE can detect subclonal 
heterogeneity, somatic homozygosity, and calculate statistical sensitivity to detect specific 
aberrations. We used ABSOLUTE to analyze ovarian cancer data and identified pervasive 
subclonal somatic point mutations. In contrast, mutations occurring in key tumor suppressor 
genes, TP53 and NF1 were predominantly clonal and homozygous, as were mutations in a 
candidate tumor suppressor gene, CDK12. Analysis of absolute allelic copy-number profiles from 
3,155 cancer specimens revealed that genome-doubling events are common in human cancer, and 
likely occur in already aneuploid cells. By correlating genome-doubling status with mutation data, 
we found that homozygous mutations in NF1 occurred predominantly in non-doubled samples. 
This finding suggests that genome doubling influences the pathways of tumor progression, with 
recessive inactivation being less common after genome doubling.
Introduction
Defining chromosome copy number and allele ratios is fundamental to understanding the 
structure and history of the cancer genome. Current genomic characterization techniques 
measure somatic alterations in a cancer sample in units of genomes (DNA mass). The 
meaning of such measurements is dependent on the tumor's purity and its overall ploidy; 
they are hence complicated to interpret and compare across samples. Ideally, copy-number 
should be measured in copies-per-cancer-cell. Such measurements are straightforward to 
interpret and, for alterations that are fixed in the cancer cell population, are simple integer 
values. This is considerably more challenging than measuring relative copy-number in units 
of diploid DNA mass in a tumor-derived sample.
Measuring somatic copy number alterations (SCNAs) on a relative basis is straightforward 
using microarrays 1,2,3,4,5 or massively parallel sequencing technology 6,7; it has been the 
standard approach for copy-number analysis since the development of comparative genomic 
hybridization (CGH) 8.
Inferring absolute copy-number is more difficult because: (i) cancer cells are nearly always 
intermixed with an unknown fraction of normal cells (tumor purity); (ii) the actual DNA 
content of the cancer cells (ploidy), resulting from gross numerical and structural 
chromosomal abnormalities, is unknown 9, 10, 11, 12, 13 and (iii) the cancer cell population 
may be heterogeneous, perhaps due to ongoing subclonal evolution 14, 15. In principle, one 
could infer absolute copy-numbers by rescaling relative data based on cytological 
measurements of DNA mass per cancer cell16, 17, 18, or by single-cell sequencing 
approaches 15. However, such approaches are not suited to support initial large-scale efforts 
at comprehensive characterization of the cancer genome19.
We began focusing on this issue several years ago, initially developing ad hoc 
techniques20, 21. We subsequently developed a fully quantitative method (ABSOLUTE) and 
applied it to several cancer genome analysis projects, including The Cancer Genome Atlas 
(TCGA) project. ABSOLUTE provides a foundation for integrative genomic analysis of 
cancer genome alterations on an absolute (cellular) basis. We used these methods to 
correlate purity and ploidy estimates with expression subtypes and to develop statistical 
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power calculations and use them to select well-powered samples for whole-genome 
sequencing in several published 22, 23, 24, and numerous ongoing projects, including breast, 
prostate, and skin cancer genome characterization. Recently, we extended ABSOLUTE to 
infer the multiplicity of somatic point-mutations in integer allelic units per cancer-cell.
Our purpose here is to: (i) to present the mathematical inference framework of the 
ABSOLUTE method, as well as experimental validation of its predictions; (ii) to apply it to 
analyze a large cancer dataset, enabling novel characterization of the incidence and timing 
of whole-genome doublings during tumor evolution; and (iii) to describe a novel integrated 
analysis of point-mutation and copy-number estimates and its application to ovarian 
carcinoma.
We describe three key mathematical features of ABSOLUTE. First, it jointly estimates 
tumor purity and ploidy directly from observed relative copy profiles (point-mutations may 
also be used, if available). Second, because joint estimation may not be fully determined on 
a single sample, it uses a large and diverse sample collection to help resolve ambiguous 
cases. Third, the model attempts to account for subclonal copy alterations and point 
mutations, which are expected in heterogeneous cancer samples.
We then report the first large-scale ‘pan-cancer’ analysis of copy-number alterations on an 
absolute basis, across 3,155 cancer samples, representing 25 diseases with at least 20 
samples. The analysis reveals that whole-genome doubling events occur frequently during 
tumorigenesis, ultimately resulting in mature cancers descended from doubled cells, bearing 
complex karyotypes. Despite evidence that genome doublings can result in genetic 
instability and accelerate oncogenesis 25,13,26 the incidence and timing of such events had 
not been broadly characterized in human cancer.
We then describe how estimates of tumor purity and absolute copy-number allow us to 
analyze sequencing data to distinguish clonal and subclonal point-mutations, and to detect 
macroscopic subclonal structure in an ovarian cancer sample. Clonal events may be 
classified as homozygous or heterozygous in the cancer cells, guiding interpretation of their 
function. In addition, the ability to quantify integer multiplicity of point mutations 
distinguishes events occurring prior to DNA gains including the mutated locus from those 
occurring later.
Finally, our data allows characterization of somatic cancer evolution with respect to genome 
doubling, which we demonstrate in ovarian carcinoma and associate with 
clinicopathological parameters.
Results
Inference of sample purity and ploidy in cancer-derived DNA
A conceptual overview of ABSOLUTE is shown in Figure 1. When DNA is extracted from 
an admixed population of cancer and normal cells, the information on absolute copy number 
per cancer cell is lost in the mixing. The purpose of ABSOLUTE is to re-extract these data 
from the mixed DNA population. This process begins by generation of segmented copy 
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number data, which is input to the ABSOLUTE algorithm together with pre-computed 
models of recurrent cancer karyotypes and, optionally, allelic fraction values for somatic 
point mutations. The output of ABSOLUTE then provides re-extracted information on the 
absolute cellular copy number of local DNA segments and, for point mutations, the number 
of mutated alleles (Figure 1).
We begin by describing the inference framework used in the ABSOLUTE method. Suppose 
a cancer-tissue sample consists of a mixture of a proportion α of cancer cells (assumed to be 
monogenomic – that is, with homogenous SCNAs in the cancer cells) and a proportion (1-α) 
of contaminating normal (diploid) cells. For each locus x in the genome, let q(x) denote the 
integer copy-number of the locus in the cancer cells. Let τ denote the mean ploidy of the 
cancer-cell fraction, defined as the average value of q(x) across the genome. In the mixed 
cancer sample, the average absolute copy number of locus x is αq(x) + 2(1 - α) and the 
average ploidy is D = ατ+ 2(1 - α), measured in units of haploid genomes.
The relative copy number of locus x is therefore:
(1)
Because q(x) takes integer values, R(x) takes discrete values. The smallest possible value is 
[2(1 - α)/D], which occurs at homozygously deleted loci and corresponds to the fraction of 
DNA from normal cells. The spacing between values [α/D] corresponds to the concentration 
ratio of alleles present at one copy per cancer cell and 0 copies per normal cell. Importantly, 
if a cancer sample is not strictly clonal, copy-number alterations occurring in substantial 
subclonal fractions will appear as outliers from this pattern (Fig. 1, Supplementary Fig. 1a-c, 
arrows).
Similar considerations have formed the basis for algorithms to infer purity and ploidy using 
allelic copy-ratios derived from SNP microarrays27-31, 32. We extend absolute copy-
inference to encompass somatic point mutations as follows:
(2)
Here, sq represents the multiplicity of the point mutation, in integer values per cancer cell 
(which cannot exceed q(x)), and Ds = α q(x) + 2(1 - α). The values of F(x) correspond to the 
expected fraction of sequencing reads that support the mutation, which depend on the 
sample purity and absolute somatic copy-number at the mutant locus, q(x).
The ABSOLUTE algorithm examines possible mappings from relative to integer copy 
numbers by jointly optimizing the two parameters α and τ (Supplementary Fig. 1c-d,h-i; 
Online Methods Eq. 5). In many cases, several such mappings are possible, corresponding to 
multiple optima.
To help resolve ambiguous cases, we used recurrent cancer-karyotype models based on large 
data sets of samples (Supplementary Fig. 2; Online Methods Eq. 8) to identify the simplest 
(that is, most common) karyotype that can adequately explain the data. This method favors 
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simpler solutions, while preserving the flexibility to identify unexpected karyotypes given 
sufficient evidence from fitting the copy-profile. Indeed, several unusual karyotypes, 
including near-haploid (<1.2n) and hyper-aneuploid (>6n) genomes, were identified using 
ABSOLUTE (Supplementary Fig. 2).
Our implementation supports copy-number inference from either total or allelic copy-ratio 
data, such that array-CGH, SNP microarray, or massively parallel sequencing data may be 
used. ABSOLUTE is available for download at http://broadinstitute.org/software/
ABSOLUTE.
Validation
We validated the purity and ploidy predictions made by ABSOLUTE on Affymetrix SNP 
microarray data using several approaches: (i) direct measurement of ploidy of 37 TCGA 
ovarian carcinoma samples by fluorescence-activated cell sorting 33 (Fig. 2a); (ii) 
Measurement of ploidy for 33 NCI60 cell lines based on spectral karyotyping34 (Fig. 2b,c); 
and (iii) DNA-mixing experiments, in which cancer cell lines were mixed with paired 
normal B-lymphocyte-derived DNAs in varying mass proportions (Fig. 2d, Online 
Methods). We also evaluated a related computational method, ASCAT30, on these data (Fig. 
2a-d, Supplementary Note 1). Although the results were broadly concordant with our 
estimates, ABSOLUTE achieved significantly more accurate results (Fig. 2a-d) on our 
validation data. Notably, we observed an apparent bias by ASCAT to underestimate cancer 
cell fraction (Fig. 2 c,d), consistent with previous reports applying ASCAT in similar mixing 
experiments based on Illumina SNP arrays30, (Figure S4), suggesting that the bias is 
independent of measurement platform.
Notably, the purity estimates produced by ABSOLUTE appeared to be more accurate for the 
bulk tumor than those derived from histological examination of frozen tumor sections 
(Online Methods, Fig. 2e). Estimates of the proportion of contaminating normal cells for 
458 ovarian carcinoma samples33 produced by ABSOLUTE were strongly correlated with a 
molecular signature of genomic methylation (Online Methods) seen in leukocytes (r2 = 0.59, 
P < 2.2×10-16, Fig. 2e), but only weakly correlated with estimates of contamination from 
histological examination (r2 =0.1, P = 2.4×10-12; Online Methods; Fig. 2e x-axis scale, 
Supplementary Fig. 4).
Estimation of tumor purity and ploidy across cancer types
We used ABSOLUTE to analyze allelic copy-ratio profiles derived from SNP arrays from 
3,155 cancer samples, comprising 2,791 tissue specimens and 364 cancer cell lines. The 
samples came from two TCGA pilot studies describing glioblastoma (GBM; 192 samples) 21 
and ovarian carcinoma (488 samples) 33, as well as 2,445 profiles incorporated from a 
previous pan-cancer copy-number analysis 35 (Online Methods). A minority of these 
samples (519 or 16.4%) could not be analyzed because they lacked clearly identifiable 
SCNAs, either because they were nearly euploid (“non-aberrant”), or were excessively 
contaminated with normal cells (“insufficient purity”), (Fig. 3a). Although sequencing data 
for somatic point mutations may have resolved these cases, such data were not available for 
the majority of samples in this cohort35.
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For the 2,636 samples with detectable SCNAs, ABSOLUTE provided purity and ploidy 
calls for 92% of cases, and designated the remaining samples as “polygenomic” 
(genomically heterogeneous) (Fig. 3a), (Online Methods; Supplementary Fig. 5). The 
fraction of called samples varied by disease type, from 34.6% (myeloproliferative disease; 
mostly non-aberrant genomes) to 96.7% (ovarian carcinoma, 100% aberrant genomes), with 
a median call-rate of 79.2% (Fig. 3a).
The distributions of estimated purity varied among cancer types, with the tested lung, 
esophageal, and breast cancer samples being the least pure on average in our dataset (Fig. 
3b). The effect of contamination was readily visible in the copy ratios of impure tumor types 
(Supplementary Fig. 6). Distributions of estimated ploidy (Fig. 3c) were qualitatively 
consistent with those derived from previously obtained cytological data for each tumor 
type 13.
A table giving the characteristics of each tumor sample, as well as predicted purity / ploidy 
values, is available as Supplementary Table 1. An additional table detailing the segmented 
absolute allelic copy number of each tumor is given as Supplementary Table 2.
Power for detection of somatic point-mutations by sequencing
Both tumor purity and ploidy will affect the local depth of sequencing necessary to detect 
point mutations. For example, suppose that a region is present at 6 copies with only 1 copy 
carrying a mutation, in a sample that has 50% contamination with normal cells. In this case, 
only 1 of 8 alleles at this locus (6 from the cancer cells and 2 from the normal cells) carry 
the mutation (Supplementary Fig. 7a). We therefore expect that the mutation will be 
observed in only 12.5% of reads. Given this allelic fraction, local sequence coverage of 33-
fold is required to detect the mutation with 80% sensitivity, assuming a sequencing error rate 
of 10-3 per base and a false positive rate controlled at <5×10-7, (Online Methods, Eq. 9, 
Supplementary Fig. 7b).
Using ABSOLUTE's estimates of purity and genome-wide integer copy-numbers, we can 
calculate the required coverage for powered detection of mutations present at specified 
allelic multiplicity per cancer cell. Similar considerations apply to detecting subclonal 
mutations, present in a fraction of cancer cells, by using fractional multiplicities 
(Supplementary Fig. 7c). We note that consideration of tumor purity in units of cells, rather 
than DNA fraction, is preferred for devising power calculations for sequencing experiments, 
since many somatic alterations of interest are expected to occur at a single copy per cancer 
cell.
We analyzed the distribution of purity and ploidy values in cancer samples analyzed for 
allelic copy number 35, 21, 33 to determine an appropriate depth of sequencing coverage 
needed to detect clonal mutations with power 0.8 in each sample. For this purpose, we 
calculated the number of reads needed to detect a mutation present in one copy at a locus 
present at the average copy number, given the sample's purity. (One could alternatively 
choose a particular percentile on the copy-number distribution.) For such a locus, we found 
that 30× local coverage would suffice for most samples (Supplementary Fig. 7d). By 
contrast, a locus of average copy number with a mutation carried in a subclone at 20% 
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frequency would require coverage of ∼ 100-fold to allow detection in about half of the 
samples (Supplementary Fig. 7e). Using these calculations and the distribution of local 
coverage along the genome (which depends on the specific sequencing technology), one can 
determine the average coverage necessary to obtain sufficient power in a predefined fraction 
of the genome (e.g. >80% power in >80% of the genome).
We then examined whole-exome sequencing data (∼150× average coverage) from 214 
TCGA ovarian carcinoma samples33 to determine whether detection power was related to 
the number of mutations actually observed. For each sample, we calculated the proportion of 
loci for which the local coverage provided at least 80% power to detect mutations present at 
single copy in a subclone present at 5%. Those samples with the lowest proportion of such 
well-powered loci tended to be 2 those in which the least mutations were detected (r2 = 0.24, 
P = 2.7×10-13; Supplementary Fig. 7f), suggesting that the failure to find such mutations 
was due to the lack of power. This result also demonstrates the importance of power 
calculations for characterization of the subclonal frequency spectrum.
Multiplicity analysis of somatic point mutations
We next used ABSOLUTE to convert the allelic-fraction of mutations to cellular 
multiplicities. For this purpose, we examined 29,268 somatic mutations identified in whole-
exome hybrid capture Illumina sequencing36 data from 214 ovarian carcinoma tumor-
normal pairs33 (Online Methods, Fig. 4a). Tumor purity, ploidy, and absolute copy-number 
values were obtained from Affymetrix SNP6.0 hybridization data on the same DNA aliquot 
that was sequenced, allowing the rescaling of allelic-fractions to units of multiplicity (Fig. 
4a,b; Online Methods, Eq. 12).
This procedure identified pervasive subclonal point-mutations in ovarian carcinoma 
samples. While many of the mutations were clustered around integer multiplicities, a 
substantial fraction occurred at multiplicities substantially less than 1 copy per average 
cancer cell, consistent with subclonal multiplicity (Fig. 4b).
Several lines of evidence support the validity of these subclonal mutations, including 
Illumina resequencing of an independent whole genome amplification aliquot, which 
confirmed both their presence (Supplementary Fig. 8a,b), and that their allelic fractions 
corresponded to subclonal multiplicity values (Supplementary Fig. 8c,d). In addition, the 
mutation spectrum seen for clonal and subclonal mutations was similar (RMSE = 0.02, Fig. 
4c), consistent with a common mechanism of origin. Power calculations showed that these 
samples were at least 80% powered for detection of subclonal mutations occurring in 
cancer-cell fractions ranging from 10% to 53%, with a median of 19% (Supplementary Fig. 
7e).
The distribution of multiplicities of the subclonal mutations was similar in the majority of 
samples (Fig. 4b) -- it rapidly increased at the sample-specific detection limit and then 
decreased in a manner approximated by an exponential decay in the multiplicity range of 
0.05 to 0.5 when pooling across all samples (not shown). In contrast, the HGS-OvCa sample 
TCGA-24-1603 (Fig. 4d-f) showed evidence for discrete “ macroscopic subclones”. 
Rescaling of subclonal SCNAs (Fig. 4d) and point mutations (Fig. 4e) to units of cancer 
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cell-fraction (Fig. 4f) revealed discrete clusters near fractions 0.2, 0.3, and 0.6 (Fig. 4f), 
implying the alterations within each cluster likely co-occurred in the same cells. We note 
that this combination of cell fractions sums to more than 1, implying that at least one of the 
detected subclones was nested inside another.
We next used ABSOLUTE to analyze the multiplicity of both the reference and alternate 
alleles, to classify point mutations as either heterozygous or homozygous in the affected 
cell-fraction (Fig. 5a-c). We considered 15 genes with mutations recently identified in these 
data 33, including 5 known tumor suppressor genes (TSGs) and 5 oncogenes (Fig. 5d). The 
frequency of homozygous mutations in known TSGs and oncogenes were significantly 
different, with a significantly elevated fraction of homozygous mutations in the TSGs (P = 
0.006, Fig. 5d) and no homozygous mutations in the oncogenes: (P = 0.012, Fig. 5d). This 
result provides evidence supporting CDK12 as a candidate TSG in ovarian carcinoma 33, 
since 7 of 12 CDK12 mutations were homozygous (P= 6.5×10-5; Fig. 5d).
Overall, TP53 had among the greatest fraction of clonal, homozygous, and multiplicity > 1 
mutations of any gene in the coding exome (Fig. 5e), demonstrating the clear identification 
of a key initiating event in HGS-OvCa carcinogenesis 37 directly from genomic data and 
independently of statistical recurrence analysis.
Whole genome doubling occurs frequently in human cancer
For many cancer types, the distribution of total copy number (ploidy) was markedly bi-
modal (Fig. 3c), consistent with chromosome-count profiles derived from SKY10, 13. 
Although these results are consistent with whole-genome doubling during their somatic 
evolution, it has been difficult to rule out the alternative hypothesis that evolution of high-
ploidy karyotypes result from a process of successive partial amplifications 12.
To study genome doublings, we used homologous copy-number information – that is, the 
copy numbers, bi and ci, of the two homologous chromosome segments at each locus. By 
looking at the distribution of bi, ci across the genome, we could draw inferences regarding 
genome doubling. Immediately following genome doubling, both, bi and ci would be even 
numbers. Following the loss of a single copy of a region, the larger of bi and ci will remain 
even, but the smaller would become odd. In fact, when we looked at high-ploidy samples, 
we discerned that the higher of bi and ci was usually even throughout the genome, consistent 
with their having arisen by doubling of the entire genome (Supplementary Fig. 9). Using 
simulations, we found that the observed profiles were unlikely to arise due to SCNAs 
occurring in serial fashion at multiple independent chromosomes (P < 1e-3; Online 
Methods).
Using such information, we could classify samples into three groups, which we interpreted 
as corresponding to 0, 1 and > 1 genome doubling events in the clonal evolution of the 
cancer. These three groups had modal ploidy values of 1.75, 2.75, and 4.0, respectively (Fig. 
6a), and also segregated into three clusters by ploidy and mean homologous copy-number 
imbalance (Fig. 6b). We interpreted this as evidence of SNCAs occurring with net losses, 
interspersed with the genome doublings. This process resulted in intermediate ploidy values 
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for the doubled clones (2.2 – 3.4N), with pervasive imbalance of homologous chromosomes 
(Fig. 6b).
The frequency of genome doubling varied across tumor types (Fig. 6c), reflecting 
differences in disease specific biology and clinical progression status. Hematopoietic 
neoplasms (MPD, ALL) had nearly no doubling events, whereas GBM, RCC, prostate 
cancer, various sarcomas, HCC, and medulloblastoma all had ∼25% incidence of doubling. 
Genome doubling was more common in epithelial cancers, with colorectal, breast, lung, 
ovarian, and esophageal cancers all having > 50% incidence of doubling (Fig. 6c). 
Esophageal adenocarcinoma had the greatest doubling incidence, consistent with previous 
reports of frequent “4N” populations at various stages of Barrett's esophagus 
progression 38,39.
Specific aneuploidies precede genome doubling
We then used ABSOLUTE to infer the temporal order of genome doubling in tumorigenesis, 
relative to SNCAs involving specific chromosome arms. In many cancer types, the fixation 
of arm-level SCNAs was inferred to occur prior to genome doubling, since both doubled and 
non-doubled samples had similar frequencies of specific arm-level SNCAs (Fig. 6d, 
Supplementary Fig. 10).
In GBM samples, LOH involving chromosomes 9 and 10, and gains of chromosome 7 
occurred at equivalent frequencies (Fig. 6d), demonstrating that the most common broad 
SCNAs in GBM occur prior to genome doubling. Gain of chromosomes 19 and 20 was 
nearly exclusive to non-doubled samples, and several arms had greater LOH frequency in 
doubled samples (Fig. 6d), suggesting that additional biological differences underlie these 
samples.
Because ABSOLUTE could not distinguish between ploidy 2N and 4N in cases with no 
observed SCNAs, we discarded such non-aberrant samples from our analysis (Fig. 3a). For 
many tumor types, such cases were rare, due to the tendency for chromosomal losses 
following doubling (Fig. 3c, Fig. 6a,b, Supplementary Fig. 9). The representation of specific 
cancer subtypes may be biased by differences in ascertainment, however.
In contrast to broad chromosomal alterations, focal SCNA events occurred at greater 
frequency in doubled genomes (Fig. 6e). Consistent with previous reports 35, 40, 41, the 
observed frequency of focal SCNAs as a function of their length (L) followed power-law 
scaling: P(L) ∝ L−α, for L > 0.5 Mb (Fig. 6e). Genome doubling was associated with a 
larger overall number of SCNAs, however we obtained estimates of α near 1 for each group 
(Fig. 6e), suggesting that the mechanism(s) by which they were generated did not greatly 
depend on ploidy.
Genome doubling influences progression of ovarian carcinoma
We next sought to correlate whole-genome doubling occurrence in ovarian carcinoma with 
other genetic and clinical features. Genome-doubled samples showed a higher incidence of 
heterozygous mutations, but correcting for sample ploidy removed this effect (Fig. 7a), 
suggesting that the per-base mutation rates are equivalent. Clonal mutations at multiplicity > 
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1 were approximately ten-fold more prevalent in doubled samples; many of these events 
likely occurred prior to the doubling event. Genome-doubled samples had a lower frequency 
of homozygous deletions (Fig. 7b) and a two-fold lower rate of clonal homozygous 
mutations (P = 1.55×10-8, Fig. 7c). We expect that many of the observed homozygous 
alterations in the doubled samples were fixed prior to genome doubling.
The lower incidence of homozygous mutations in genome-doubled samples may reflect the 
fact that more events are required to render a mutation homozygous in a genome-doubled 
sample (although the effect may be partially offset, however, by a possible increase in 
genetic instability following doubling, e.g., by centrosome duplication 42). These 
considerations suggest that genome-doubled samples evolve via distinct trajectories, because 
inactivation of tumor suppressors may occur less frequently following doubling.
We note that 13 of the 15 detected point mutations in the tumor suppressor NF1 occurred in 
the 93 ovarian samples that had not undergone genome doubling (P = 0.002; Fisher's exact 
test), and these mutations were uniformly homozygous (not shown). This is consistent with 
selection for recessive inactivation of NF1, a typical pattern for a tumor suppressor gene. It 
also suggests that non-genome-doubled ovarian carcinoma samples evolved via a distinct 
trajectory, rather than being precursors to doubled samples. If not, many NF1 mutations 
would be homozygous with multiplicity > 1 in doubled samples, as is seen for TP53.
Finally, we noted that genome-doubled samples were associated with a significant increase 
in the age at pathological diagnosis (Fig. 7d) and with a significantly greater incidence of 
cancer recurrence (Fig. 7e).
Discussion
We here report the development of a reliable high-throughput method to infer absolute 
homologous copy-numbers from tumor-derived DNA samples, as well as multiplicity values 
of point mutations (ABSOLUTE). It may be possible to extend ABSOLUTE to other types 
of genomic alterations, such as structural rearrangements and small insertions/deletions, 
although this may require longer sequence reads in order to ensure accurate sequence 
alignment.
ABSOLUTE analysis of SCNAs demonstrated that many of the copy-number alterations 
analyzed were fixed in the cancer lineage represented in the sample (Fig. 3). This was 
recapitulated in ovarian cancer by somatic point-mutations, many of which were fixed at 
integer multiplicity (Fig. 4b). Classification of point mutations based on their multiplicities 
may help distinguish tumor suppressors and on cogenes (Fig. 5d). Knowledge of discrete 
tumor copy-states, subclonal structure, and genome doubling status provides a foundation 
for further reconstruction of the phylogenetic relationships within a cancer and the temporal 
sequence by which a given cancer genome arose43, 44, 45.
ABSOLUTE provides a framework for the design of studies using genomic sequencing to 
detect variant alleles in cancer tissue samples, based on calculation of sensitivity to detect 
mutations as a function of sample purity, local copy-number and sequencing depth 
(Supplementary Fig. 7). The high accuracy of tumor purity and ploidy estimates produced 
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by ABSOLUTE based on SNP microarray data (Fig. 2) make it possible to determine the 
sequencing depth required for a given sample or to select suitable samples given a fixed 
sequencing depth. Such considerations are vital to the interpretation of subclonal point-
mutations (Supplementary Fig. 7f, 10).
Analysis of the predicted absolute allelic copy-number profiles across human cancers 
produced by ABSOLUTE shed new light on cancer genome evolution. The observed SCNA 
profiles (Supplementary Fig. 9) were consistent with a common trajectory consisting of an 
early period of chromosomal instability followed by the emergence of a stable aneuploid 
clone, as previously described 11. Our data further indicate that genome doublings occur in a 
subset of cancer cells already harboring arm-level SCNAs characteristic of the 
corresponding tumor type. The genomes of these cancers were therefore shaped by selection 
at chromosomal arm-level resolution prior to doubling and further clonal outgrowth (Fig. 6d, 
Supplementary Fig. 10).
These findings are broadly consistent with an earlier interpretation of primary breast cancer 
FACS/SKY profiles 46, and has recently been recapitulated in studies of macro-dissected 
and ploidy-sorted cell populations 14, and single cell sequencing15 of primary breast tumors. 
We note that this model represents a departure from the idea that tetraploidization is an 
initiating event 47,13,26,48,49. In addition, the association of genome lineage (Fig. 6c) and 
with age at diagnosis in ovarian carcinoma (Fig. 7d) is consistent with a recently described 
mechanism linking telomere crisis, DNA damage response, and genome doubling in 
cultured mouse embryonic fibroblasts 48.
The analysis of clonality presented in this work offers a path forward for clinical sequencing 
of cancer, and provides means to address recently reported concerns regarding intra-tumor 
heterogeneity50, 14, 44, 15, 45, 51,52. Analysis using ABSOLUTE can identify alterations 
present in all cancer cells contributing to the DNA aliquot (Fig. 1), even if such clonal 
alterations correspond to the minority of observed mutations. Such alterations are candidate 
founding oncogenic drivers for a given cancer, which may be the preferred therapeutic 
targets. Further characterization of subclonal somatic alterations in cancer may become 
important for understanding variable response to targeted therapeutics, with the clonalilty of 
targeted mutations potentially affecting response level.
Online Methods
Inference of purity, ploidy, and absolute somatic copy-numbers
populations presents a challenge to such analysis, both cytological 10 and genomic data 11 
have supported this assumption, as have reports of similar SCNA profiles obtained from 
paired primary and metastatic lesions Homologue-specific copy ratios (HSCRs; copy-ratio 
estimates of both homologous chromosomes), are preferred for analysis with ABSOLUTE, 
and were used for all analyses in this study Although ABSOLUTE can be run on total copy-
ratio data (e.g. from array CGH or low-pass sequencing data), we do not present such results 
here. The use of HSCRs reduces the ambiguity of copy profiles. For example, the total copy-
ratio profile of a sample without SCNAs would be equivalent for ploidy values of 1,2,3, etc., 
however the HSCR profile would rule out odd ploidy values, since these would not be 
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consistent with equal homologous copy-numbers. In addition, since subclonal SCNAs will 
generally affect only one of the two HSCR values in a given genomic segment, the ratio of 
clonal to subclonal SCNAs genome-wide is generally higher when considering HSCRs 
rather than only total copy-numbers.
HSCRs were derived from segmental estimates of phased multipoint allelic copy-ratios at 
heterozygous loci using the program HAPSEG 53 on data from Affymetrix SNP arrays. As 
part of this procedure, haplotype panels from population linkage analysis HAPMAP3 54 
were used in conjunction with statistical phasing software BEAGLE 55 in order to estimate 
the phased germline genotypes at SNP markers in each cancer sample. This increased our 
sensitivity for resolving these genotypes, since it naturally exploits the local statistical 
dependencies between SNPs 53. In addition, this allowed greater resolution of small 
differences between homologous copy-ratios, since phase information from allelic 
imbalance of heterozygous markers due to SCNA could be combined with the statistical 
phasing from the haplotype panels 53.
Identification and evaluation of candidate tumor purity and ploidy values
We describe identification of candidate tumor purity and ploidy values and calculation of 
their SCNA-fit log-likelihood scores using a probabilistic model. This is accomplished by 
fitting the input HSCR estimates with a Gaussian mixture model, with components centered 
at the discrete concentration-ratios implied by eq. 1. The model also supports a small 
fraction of subclonal events which are not restricted to the discrete levels. Candidate 
solutions are identified by searching for local optima of this likelihood over a large range of 
purity and ploidy values. This results in a discrete set of candidate solutions with 
corresponding SCNA-fit likelihoods (eq. 1, Supplementary Fig. 1d,h).
These scores quantify the evidence for each solution contributed by explanation of the 
observed HSCRs as integer SCNAs. These computations are independent for each sample. 
The input data consist of N HSCRs xi, i ∈ {1, …, N}. Each of these is observed with 
standard error σi, and corresponds to a genomic fraction denoted wi. Each of the xi is 
assumed to have arisen from either one of Q integer copy-number states: Q = {0,1, …, Q − 
1}, or an additional state Z corresponding to subclonal copy-number. We refer to the 
collection of possible copy-states as S = Q ∪ Z. We define Q + 1 indicators s for the copy-
state of each segment, with p(si) representing the probability of segment i having been 
generated from state s ∈ S. The integer copy-states of S are indexed by q ∈ Q; the non-
integer state is denoted by z.
The expected copy-ratio corresponding to each integer copy-number q(x) in a tumor sample 
is given by equation 1. Note that when homologous copy-ratios are used, this equation 
becomes:
(3)
since HSCRs are measured relative to haploid concentrations, as opposed to the diploid 
values assumed by eqn. 1. D is related to tumor purity and ploidy (α and τ) (eq. 1, 
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Supplementary Fig. 1). The observed xi are modeled with a mixture of Q Gaussian 
components located at μ = {μq∈Q} representing integer copy-states Q and an additional 
uniform component Z. The mixture Z allows segments to be assigned non-integer copy 
values so that occasional subclonal alterations or artifacts do not dramatically impact the 
likelihood.
(4)
 and  denote the normal and uniform densities, respectively. The free parameter σH 
represents sample-level noise in excess of the HSCR standard-error σi, which might 
represent a moderate number of related clones in the malignant cell population, ongoing 
genomic instability, or excessive noise due to variable experimental conditions. The mixture 
weights θ = {θs∈S} specify the expected genomic fraction allocated to each copy-state. The 
parameter d represents the domain of the uniform density, corresponding to the range of 
plausible copy-ratio values (we used d = 7).
Some complication arises due to the fact that the data consist of copy-ratios calculated from 
a segmentation of the genome. For consistent interpretation, the mixture weights (P(si|wi, θ)) 
must be calculated for each segment separately, taking into account the variable genomic 
fraction wi. This is accomplished by constraining the canonical averages of genomic mass 
allocated to each copy-state to match those specified by θ:
where 〈·〉  denotes the average over all configurations {si}, weighted by the function  = 
P(si|wi,λ) This density corresponds to the maximum entropy distribution over s subject to 
these constraints:
where s# indicates the order of state s in a sequence of copy-states, beginning with 0. Values 
of the Q Lagrange multipliers λ are determined via Nelder-Mead optimization of L2 loss:
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This approximation allows for robustness of the SCNA-fit score to over-segmentation of the 
data. The likelihood of a given segment i is then calculated as:
and the full log-likelihood of the data is then:
(5)
We define the parameterization b = 2(1 − α), δτ = α/D, which determines μ via eq. (3). 
Candidate purity and ploidy solutions for a tumor sample are identified by optimization of 
eq. (5) with respect to b and δτ. Calculation of eq. (5) requires estimates of θ and σH, which 
are not known a priori. We make an approximation (scale-separation) assuming that 
locations of the modes of eq. (5) are invariant to moderate fluctuations in these parameters. 
A provisional likelihood for each xi may then be calculated by
Candidate purity and ploidy solutions are then identified by optimization of
initiated from all points in a regular lattice spanning the domain of b and δτ. The parameter 
σP was set to 0.01 for this study. We verified that the above approximation identified modes 
equivalent to those obtained through a full Metropolis-Hastings Markov chain Monte Carlo 
(MCMC) simulation (data not shown). The approximation allows for much simpler 
computations to be used.
The SCNA-fit score for each solution is calculated after optimization of σH:
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with the elements of θ calculated for each value of σH by:
(6)
The final calculation of the SCNA-fit log-likelihood for each mode is obtained by inserting 
μ̂, θ ^, and σ̂H into eq. (5). Estimates of the copy-state indicators for each segment are 
calculated as:
Note that each q̂i is a vector representing the posterior probability of each Q ∈ Q integer 
copy-states, corresponding to the copy-ratios (locations) μ.
Genome-wide absolute copy-profiles are over-determined with respect to DNA ploidy 
estimates. An alternate estimate of ploidy may be calculated as the expected absolute copy-
number over the genome:
(7)
By definition, this quantity (τ̂g) is an alternate estimate of cancer ploidy (note an additional 
factor of 2 is added when HSCRs are used). Because (τ̂g) is a weighted average over discrete 
states in the modeled data, it is expected to be more robust to experimental fluctuations that 
shift or scale the copy-profile slightly. Note that, for this computation, the q̂ij were 
calculated with θ̂z = 0, so that the above expectation is over integer states only.
We verified that these estimates were generally close to the values of (τ̂) obtained by 
optimization of the SCNA-fit likelihood (RMSE=0.26, Supplementary Fig. 12a). However, 
we noted a relationship between the level of discordance between ploidy estimators and the 
mean of the calibrated data (Supplementary Fig. 12b). Noting that correctly calibrated copy-
ratio data always has mean = 1, we examined whether the miscalibration was due to scaling 
bias in the data. We found that this model explained nearly two thirds of the discordance 
between the two estimates (corrected RMSE=0.09, Supplementary Fig. 12c), by which we 
inferred that scaling biases dominated our miscalibration. This is significant, as such biases 
do not effect the estimation of tumor purity (Supplementary Fig. 12).
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Two additional transformations of the copy-state locations μ are used when copy-ratios are 
measured using microarrays. The first of these accounts for the effect of attenuation with an 
isothermal adsorbtion model 7:
where the value ϕ̂ parameterizes the attenuation response in a given sample, and is estimated 
via HAPSEG. The second transformation is a variance stabilization for microarray data 
adapted from 56:
where ση and σε represent multiplicative and additive noise scales for each microarray, 
estimated by HAPSEG. This transformation is applied to the marker-level data during 
estimation of the xi values, after which their distribution is approximately normal. The 
normal mixture component specified in (4) then becomes h(xi) = h(g(μq))+εi, and the 
corresponding likelihood calculations are performed under these transformations.
Karyotype models
Additional information is generally required in order to reliably select the correct tumor 
purity and ploidy solution from the set of candidates identified by fitting the model in (4). In 
a given tumor sample, several combinations of theoretically possible purity, ploidy, and 
copy number values may map to equivalent copy ratios (Supplementary Fig. 1c,h). 
Furthermore, the presence of subclonal SCNAs may result in a spuriously high ploidy 
solution with an implausible karyotype receiving a greater SCNA-fit likelihood by over-
discretizing the copy profile, allowing their assignment to integer copy-levels 
(Supplementary Fig. 1h-j).
ABSOLUTE models common cancer karyotypes by grouping tumor sets according to 
similarities in their absolute homologous copy-number profiles (Supplementary Fig. 2). 
These models are constructed directly from the tumor data in a ‘boot-strapping’ fashion, 
whereby a subset of tumors with relatively unambiguous profiles (e.g., due to high purity 
values) is used initialize the models, iteratively allowing more tumors to be called, etc. 
Previous cytogenetic characterizations of human cancer were used to guide this process 13. 
These models enable calculation of a karyotype likelihood, for each candidate purity/ploidy 
solution, reflecting the similarity of the corresponding karyotype to models associated with 
the specified disease of the input tumor sample (8). Integration of the SCNA-fit and 
karyotype likelihoods favors robust and unambiguous identification of the correct purity and 
ploidy values in many tumor samples (Supplementary Fig. 1d,h).The selection of a solution 
implying a less common karyotype requires greater evidence from the SCNA-fit of the copy 
profile.
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Prior knowledge of karyotypes characteristic of a particular disease is summarized as a 
mixture of K multivariate multinomial distributions over the integer homologous copy-states 
Q = [0,7] of each chromosome arm. For a given candidate purity and ploidy solution, the 
corresponding segmental copy-state indicators for each segment i, q̂ij, are summarized into 
estimates of the J arm-level homologous copy-numbers, denoted Ĉ. The karyotype log-
likelihood score is calculated as:
(8)
where wi denotes the weight of each mixture component. The karyotype models Ki are J × Q 
SCNA probability matrices obtained by clustering arm-level homologous copy-states of 
modeled copy-profiles using the standard expectation-maximization (EM) algorithm 57 for 
multinomial mixtures. This calculation identifies groups of disease subtypes with similar 
genomic copy profiles (Supplementary Fig. 2). Note that copy-states for both homologues of 
each arm are modeled (J = 78). Karyotype scores for samples with only total copy-ratio data 
are calculated using convolution of the multinomial probabilities for the two homologous 
chromosomes.
The number of clusters K for each disease was chosen by minimizing the Bayesian 
information criterion (BIC) complexity penalty: −2L̂k + KJ log (N), where L̂k indicates the 
sum of ℒK values over the N input samples, computed using K clusters. In order to avoid 
local minima, the EM algorithm was run 25 times for each value of K ∈ [2,8] with 
randomized starting points and the best model was retained.
The models were constructed in a semi-automated fashion by seeding with relatively 
unambiguous copy-profiles. As tumors were added, the use of recurrent karyotypes clearly 
identified the correct solutions of additional samples, etc. For example, LOH of chr17 
occurs in nearly 100% of ovarian carcinoma samples 33, allowing the model to learn that 
solutions implying LOH of chr17 are likely to be correct. In total, models for 14 disease 
types were created. Diseases with fewer than 40 samples called by ABSOLUTE were 
omitted from this procedure. In addition, a “master” model was created by combining called 
primary cancer profiles. This model was used for diseases with no specific karyotype model.
Limitations of joint purity/ploidy inference from copy-profile data
Accurate calibration of both the SCNA-fit and karyotype models to the true level of 
certainty implied by the data would allow for assignment of probabilities to each candidate 
solution; we do not believe that the models we have presented here sufficiently capture the 
complexity of cancer genomes to allow for such interpretations. Even with manual review, 
analysis with ABSOLUTE may occasionally result in incorrect interpretations, for example 
genome-doubling without subsequent detectable gains or losses would result in a solution 
implying half the true ploidy value, which in some cases may correspond to a plausible 
karyotype model. Alternately, when multiple subclonal SCNAs appear close to the 
midpoints between adjacent clonal peaks, a solution implying twice the true ploidy may be 
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chosen. We note that samples with no reliably detected SCNAs could not be called in our 
framework (ploidy 2N or 4N; purity undetermined). Such samples were therefore excluded 
from downstream analysis (see below). Estimation of inference error-rate requires 
independent measurement of sample ploidy. Further validation experiments in diverse tumor 
types will help to clarify any disease specific caveats.
We note that the use of somatic mutation allelic-fractions, combined with the SCNA copy-
ratios, generally allows for increased sensitivity for samples with few SCNAs. In addition, 
the mutation data helps distinguish genome-doubling ambiguity in purity/ploidy estimation, 
although they do not inform ambiguities of the type b′ = b + 2(1-α)/D (Supplementary Fig. 
1d,i, eq. 1). Thus, combined analysis generally facilitates obtaining higher call-rates using 
ABSOLUTE (not shown).
Fortunately, many samples in our pan-cancer SNP array dataset were consistent with 
frequent SCNA both before and after genome doubling, enabling unambiguous inference for 
many samples without use of somatic point-mutation data. This aspect of cancer genome 
evolution was noted previously in breast cancer cytogenetic data 46. We note that manual 
review of ABSOLUTE results was performed prior to generation of the FACS validation 
data or analysis of the NCI60 cell-line ploidy estimates (Fig. 2a,b).
Identification of samples refractory to purity/ploidy inference
In order to facilitate rapid analysis of many cancer samples used in this study, ABSOLUTE 
was programed to automatically identify copy profiles that cannot be reliably called and to 
classify them into informative failure categories (Fig. 3a), which were defined by the 
following criteria. Define m̂ as the sorted vector of posterior genome-wide copy-state 
allocations (θ̂), so that m1̂ represents the greatest element of θ̂ (the modal copy-state). This 
vector was constructed with θ0 replaced by 0 if θ0 < 0.01 and b < 0.15, so that germline 
copy-number variants (CNVs) or regions of inherited homozygosity are not confused with 
small SCNAs implying very pure samples. The categories are then:
1. non-aberrant: m3̂ < 0.001, m̂2 < 0.005, σ̂H < 0.02
2. insufficient purity: m̂3 < 0.001, m̂2 < 0.005, σĤ ≥ 0.02
3. polygenomic: θẑ > 0.2.
These criteria were applied to the top-ranked mode for each sample (combined SCNA-fit 
and karyotype scores). Several examples of each outcome are shown in Supplementary Fig. 
5. The above designations led to reasonably good concordance of automated calls with those 
obtained after manual review. We note that the use of somatic point-mutation data increases 
the calling sensitivity within these sample categories.
Cancer cell-line DNA mixing experiment
DNA extracted from two cancer cell lines (HCC38, HCC1143) was mixed with DNA from 
matched B-lymphocyte cell lines (HCC38BL, HCC1143BL) in various proportions, and 
hybridized to Affymetrix 250 K Sty SNP arrays. Stock DNA aliquots were created for each 
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cell-line by normalization of DNA concentration to 50ng/μl. Mixing of cancer and matched 
B-lymphocyte DNA to each required mixing fraction was done by volume.
FACS analysis of primary tumor samples
Formalin-fixed and paraffin-embedded blocks from ovarian serous carcinoma cases were 
available from tumor-sections corresponding to the frozen blocks from which DNA-aliquots 
were obtained for SNP-array hybridization. Multiple curls containing at least 70% tumor cell 
nuclei were cut to an aggregate thickness of 150 microns. Sections were disaggregated and 
labeled with propidium iodide (DNA stain). FACS was performed to determine ploidy.
Determination of tumor purity via pathology review
Frozen ovarian serous cystadenocarcinoma specimens were collected from multiple hospital 
tissue banks and maintained frozen in liquid nitrogen vapors. A tissue portion was created 
with two flanking H&E slides (arbitrarily named top and bottom) as follows: tissues were 
mounted in optimal cutting temperature media (OCT) and brought to -20°C. A 4μm frozen 
section (top slide) was cut with a cryostat (Leica Microsystems, Wetzlar, Germany). A 
specimen for molecular extraction was created by shaving 100 mg of tumor tissue from the 
tissue face with a scalpel, then a second 4μm frozen section was cut (bottom slide). An H&E 
stain was conducted on both slide tissue sections using an Autostainer XL with integrated 
coverslipper (Leica). Digital images of slides were created at 20× resolution using a 
Scanscope XT (Aperio, Vista, CA, USA). Board-certified pathologists conducted the 
pathology review remotely via ImageScope software (Aperio). Pathologists initially 
reviewed each slide at low magnification to determine low power microscopic morphology, 
then increased magnification to 20× and reviewed 10 representative high power fields on 
each slide. Diagnosis of ovarian serous cystadenocarcinoma was verified, and tumor purity 
was determined as the proportion of tumor nuclei present compared to the total nuclei 
present on the slide. The tumor purity of the extracted specimen was calculated as the 
average purity score of the top and bottom slides. Quality control included a random review 
of 10% of slides by a second pathologist to verify consistency of reads.
Leukocyte methylation signature
DNA methylation data for 489 high stage, high grade serous ovarian tumors and eight 
normal fallopian tube samples was obtained from http://tcga.cancer.gov/dataportal/. In 
addition, buffy coat samples from two female individuals were obtained. All data were 
generated with Illumina Infinium HumanMethylation 27 arrays, which interrogate 27,578 
CpG sites located in proximity to the transcription start sites of 14,475 consensus coding 
sequencing in the NCBI Database (Genome Build 36). The level of DNA methylation at 
each probe was summarized with beta values ranging from 0 (unmethylated) to 1 
(methylated) 58.
The leukocyte methylation signature was derived as follows. Each probe was ranked by the 
difference in mean beta value in buffy coat and fallopian tube samples. We retained the 100 
probes with the largest positive difference and the 100 with the largest negative difference 
between mean DNA methylation in normal fallopian tube tissues and peripheral blood 
leukocytes, designated BC and FT, (buffy coat and fallopian tube enriched, respectively). 
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Let Tik denote the beta value for probe k in tumor sample i. Let Bk denote the average beta 
value of buffy coat samples for each probe. Let Tk denote the minimum observed beta value 
across all tumor samples for the BC probes and the maximum for the FT probes. Denote by 
fB the fraction of buffy coat components in the sample, then we have the following equation 
for each probe: Tik = BkfB + Tk(l−fB). Solving this equation for fB gives: fB = (Tik − Tk)/(Bk − 
Tk). The values of fB for each of the 200 probes in the signature were calculated and a kernel 
density estimate was obtained. The leukocyte signature was then calculated as the mode of 
this density estimate.
Selection of datasets
We analyzed 2445 Affymetrix 250 K Sty SNP samples from a previous pan cancer survey 35 
containing 3131 cancer samples. Because our processing of the data required use of the 
Birdseed algorithm 59, external datasets lacking diploid PCR controls could not be used. In 
addition, cancer types with fewer than 20 samples were excluded. In addition, 680 
Affymetrix SNP6.0 samples were taken from the TCGA GBM 21 and HGS-OvCa 33 studies, 
as well as 30 cell-line samples, bringing to total sample count to 3155. The complete table of 
cancer samples analyzed is available as Supplementary file 1. The complete table of 
ABSOLUTE results is available as Supplementary file 2.
Power calculation for somatic mutation detection in cancer tissue samples
We develop a framework for calculation of statistical power for the detection of mutations. 
Power to detect a variant depends on the allelic fraction f and local depth of coverage n. To 
calculate power, we model the idealized scenario in which random sequencing errors occur 
uniformly with rate ε. We calculate a minimum number of supporting reads k such that the 
probability of observing k or more identical non-reference reads due to sequencing error is 
less than a defined false-positiverate (FPR):
Where
Variants with ≥ k supporting reads are then considered detected. We specified the 
sequencing error rate ε = 1 × 10−3 and FPR = 5× 10−7 for all computations in this study. 
Power is then calculated as:
(9)
Where
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We consider the case of detecting clonal somatic variants present at a single copy per cancer 
cell in cancer-tissue derived DNA samples. Given estimates of purity (α) and local absolute 
copy-number (qt), the allelic fraction of such variants is:
(10)
Power is calculated in such cases as Pow(n, δ).
In order to simplify the relationship between power and tumor purity/ploidy for presentation 
in Supplementary Fig. 7, we considered the detection power of the expected locus, over the 
genome-wide copy average. Power as such is determined by the sample allelic index δτ = 
α/D, which is solely a function of tumor purity/ploidy (eqn. 1). Expected power is obtained 
by using allelic fraction f =δτ in eq. (9). This calculation differs only in the substitution of 
expected genomic copy-number, i.e. ploidy (τ)for the local copy-number qt in eq: (10).
Power for expected subclonal variants present in fraction sf of cancer cells is given by 
Pow(n, sfδτ) This calculation was used for Supplementary Fig. 7c,e. Local copy calculations 
using Pow(n, sfδ) were used for Supplementary Figs. 7f, 11.
Detection of somatic point mutations in ovarian carcinoma
We analyzed whole-exome hybrid capture Illumina sequencing (WES) 36 data from 214 
ovarian carcinoma tumor-normal pairs previously analyzed by the TCGA consortium 33. We 
used the program muTect (K. Cibulskis, et al., in preparation.) We have used a newer 
version of the program muTect than used in previous analysis of this data 33. The primary 
improvement in the new version is a reduction in the prior that somatic mutations be at an 
allelic fraction of 0.5, allowing greater sensitive at low allelic-fraction mutations, such as 
clonal events in impure samples, or to subclonal mutations. This procedure resulted in 
29,268 somatic mutations.
Inference of point mutation multiplicity
We develop a probabilistic model for inference of the integer multiplicities for both 
germline and somatic variants, based on knowledge of tumor purity and genome-wide 
absolute copy-numbers. Denote the absolute homologous copy-numbers at a mutant locus as 
q1 and q2, with q1 ≥ q2. The possible multiplicities of germline variants are then:
where qt = q1 + q2. Under the assumption that all somatic point-mutations arise uniquely on 
a single haplotype, the possible multiplicities are:
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Note that when only total copy-ratio data are available, q2 above is unknown, and qt is used 
instead.
Germline mutations are generally present in both the cancer and normal cell populations, 
with somatic copy-number alterations affecting the allelic fraction. A heterozygous variant 
in the germline, with multiplicity gq in the cancer genome, has allelic fraction:
(11)
Where as the allelic fraction of homozygous germline variants is 1 regardless of α. For 
somatic point mutations, the expected allelic fraction at multiplicity sq is fsq = sqδ, with δ as 
in eq. (10).
Consider an observed somatic point-mutation of unknown copy sq ∈ sq, observed allelic 
fraction f̂, and with n total reads covering the locus. The complete likelihood of f̂ may 
represented as a mixture of beta distributions corresponding to each element of sq, plus an 
additional component S corresponding to subclonal states:
(12)
where wSq ∈ wq specify mixture weights for each state in sq, and wSc specifies the subclonal 
component weight. The subclonal component S is specified by composing a Beta 
distribution (modeling sampling noise) with an exponential distribution over subclonal 
cancer-cell fractions, having a single parameter λ:
Note the change of coordinates in the exponential component using δ; this allows modeling 
in consistent units of cancer-cell fractions, regardless of tumor purity and local copy-number 
(note this distribution is renormalized on the unit interval). The probability of a given integer 
copy-state sq may then be calculated as:
Similarly, the probability that a given mutation is subclonal is calculated as:
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For the computations in this study we fixed λ = 25, wsq to 0.25, and wSc to 0.75, which 
produced a fit to the combined-sample mutation-fraction distribution (Fig. 4b). The results 
presented in Fig. 4 were robust to various settings.
Optimization of mixture components weights corresponding to integer somatic multiplicities 
may be accomplished in a manner similar to that described for the SNCA mixture model in 
eq. (6). A Dirichlet prior may be specified as a vector of pseudo-counts equivalent to prior 
observations of each multiplicity value. Weights are then calculated as the mode of the 
posterior Dirichlet calculated from the observed counts. These computations are used to 
calculate a mutation-score likely for each purity ploidy mode when ABSOLUTE is run with 
paired SCNA and somatic point mutation data.
Simulation of cancer-genome evolution to support genome-doubling inferences
A simple simulation was performed to obtain P-values for the probability that an observed 
configuration of homologous copy-numbers could be produced from a serial process of 
independent gains and losses. Genome-wide homologous copy-numbers are summarized at 
chromosome-arm resolution as integer gains/losses (total of 78 states). We then fix the total 
number of gains/losses N for the sample, and calculate rates for each arm, which are 
normalized to probabilities. Simulation of the sample is performed by independently 
sampling N gains and losses from these probabilities. This was repeated 1000 times for each 
sample, keeping track of the number of times M that the extent of even high homologous 
copy-number present in the observed sample was attained or exceeded. The P-value is then: 
P = M/1000, if M > 0, otherwise P < 0.001.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Overview of tumor DNA analysis using ABSOLUTE
A constant mass of DNA is extracted from a heterogeneous cell population consisting of 
cancer and normal cells. This DNA is profiled using either microarray or massively parallel 
sequencing technology, giving a genome-wide profile of DNA concentrations (blue lines). 
ABSOLUTE uses statistical models of recurrent cancer karyotypes to interpret the DNA 
concentrations as discrete copy states corresponding to predominantly clonal somatic copy 
number alterations, although some subclonal alterations are often present. If somatic point 
mutation data are available (from sequencing of the DNA), then the allelic fractions 
(fraction of sequencing reads bearing the non-reference allele) of these mutations may be 
used help to interpret the DNA concentrations. In addition, the allelic fractions may be 
reinterpreted as integer allelic copies per cancer cell (multiplicity), potentially revealing 
subclonal point mutations.
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Figure 2. ABSOLUTE method validation and comparison a-d Performance of ABSOLUTE and 
ASCAT on 4 validation assays
RMSE: root mean squared error. P-values were calculated on the squared errors using the 
paired one-sided Wilcoxon test (*: P < 0.05, **: P < 0.001). See Supplementary Note 1 for 
the ASCAT2.1 protocol.
a, FACS-based ploidy measurements vs. inferred ploidy estimates for 37 primary tumor 
samples.Dashed line indicates y=x.
b, SKY-based ploidy measurements vs. inferred ploidy estimates for 33 cancer cell-lines. 
Dataare displayed as in a.
c, Estimated purity of the 33 cell lines shown in (b) Dashed horizontal line indicates the 
truepurity (1.0).
d, Cancer-normal DNA mixing experiment results for two cell lines. DNA from each 
cancercell line was mixed with DNA from the matched B-lymphocyte in varying 
proportions (x-axis).(top) predicted vs. true DNA mixing fractions compared to the y=x line 
(dashed). (bottom)predicted cancer cell-line ploidy vs. mixture purity. The copy-profile of 
several samples wasmisinterpreted (x's); these points were not included in the RMSE 
calculations. Ploidy estimateswere generally consistent with previous SKY analysis of these 
cell lines: http://www.path.cam.ac.uk/∼pawefish/cell%20line%20catalogues/breast-cell-
lines.htm.
e, Leukocyte methylation signature enrichment in tumors of histologicaly 
underestimatedpurity. HGS-OvCa samples are shown grouped according to the indicated 
histological purityestimates (x-axis)33. Black horizontal lines indicate the median purity of 
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each group, asestimated by ABSOLUTE (y-axis). The color of each point corresponds to the 
degree to whichthat sample's methylation profile resembled that of purified leukocytes 
(Online Methods).
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Figure 3. Pan-cancer application of ABSOLUTE
a, ABSOLUTE result types: (i) ‘called’ -- unique purity/ploidy solution; (ii) ‘non-aberrant’ 
--sample has no detectable somatic copy-number alterations; (iii) ‘insufficient purity’ – 
insufficient fraction of cancer cells; (iv) ‘polygenomic’ discrete copy-ratio levels could not 
be determined. See Online Methods and Supplementary Fig. 5 for a description and 
examples of each result type.
b, Distribution of estimated tumor purity for several datasets. The number of called tumor 
samples in each group is shown in parentheses. We note that, because heavily contaminated 
tumors are difficult to call using ABSOLUTE, several of these distributions are biased 
towards higher purity samples.
c, The number of called tumor samples in each group is shown in parentheses. Because 
tumors without SCNAs cannot be called using ABSOLUTE, these distributions do not 
incorporate the prevalence of such samples.
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Figure 4. Characterization of subclonal evolution in ovarian cancer by integrative analysis of 
SNP array and whole-exome sequencing data
a, Histogram of allelic fraction (alternate/total read-count) values for 29,628 somatic point-
mutations detected in 214 primary HGS-OvCa samples33.
b, Allelic fractions for the mutations shown in (a) were converted to point estimates of 
integer allele-counts per cancer cell (cellular multiplicity; x-axis) by correcting for sample 
purity and local copy-numbers. Subclonal mutations were identified using the model defined 
in equation 10.
c, The fraction of each of the 6 distinguishable nucleotide substitutions for clonal vs. 
subclonal point-mutations. The solid grey line indicates y=x. RMSE: root mean squared 
error.
d-f, Analysis of distinct subclonal populations in HGS-OvCa sample TCGA-24-1603 
(purity=0.96, ploidy= 1.75).
d, Tumor SCNA profile with modeled absolute copy-numbers, as in Supplementary Fig. 
1c,h. Regions of normal homologous copy-number = 1 are grayed out, clonal SCNAs are 
brown.Subclonal SCNAs (light blue) appear in several clusters (arrows).
e, Point mutation allelic-fraction profile. Each solid curve corresponds to a single mutation, 
withthe density according to the posterior (Beta) distribution implied by the observed allelic 
fractionand local read depth (Online Methods, Eq. 12). Color indicates degree of 
classification as clonalor subclonal, as in (b). Dashed curves indicate summed density of 
individual posteriors.
f, SCNAs from (d) and point mutations from (e) were rescaled to units of cancer cell 
fraction. Subclonal cancer cell fractions of ∼0.2, 0.3, and 0.6 are supported both by SCNAs 
and point mutations (purple, blue, and orange arrows, respectively; see corresponding copy 
ratios in d).
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Figure 5. Classification of somatic mutations by multiplicity analysis in 214 primary HGS-OvCa 
tumor samples
a, Empirical density estimate of allelic concentration-ratios, which are obtained by 
multiplication of the allelic fraction by the copy-ratio at that locus.
b, Density estimate of allelic multiplicity estimates, as in Fig. 4b, for reference vs. mutant 
allele.Mutations were classified into the four indicated categories according to their mutant 
andreference allele multiplicity.
c, The density estimates of allelic concentration-ratios are shown for each of the four 
mutation classes in b are shown superimposed.
d, Mutation classification profiles of genes identified as significantly recurrent in HGS-
OvCa33, aswell as several COSMIC genes with previously observed mutations in these data. 
Note that onlyindividual point mutations were considered here; the possibility of recessive 
inactivation viamultiple events (compound heterozygosity) was not considered. Histograms 
of gene classification fractions for 1412 genes having at least 5 recurrent mutations. Dashed 
vertical lines denote the 5th (top) and 95th (other) percentiles of each distribution. No 
mutations occurring at multiplicity > 1were observed in NF1 (not shown).
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Figure 6. Incidence and timing of whole genome doubling events in primary cancers
a, b, Ploidy estimates were obtained from ABSOLUTE. Mean homologue imbalance was 
calculated as the average difference in the homologous copy numbers at every position in 
the genome. Genome doubling status was inferred from the homologous copy numbers 
(Online Methods, Supplementary Fig. 9).
c, MPD – myeloproliferative disease, ALL – acute lymphoblastic leukemia, GBM - 
Glioblastomamultiforme, RCC - renal cell carcinoma, HCC - hepatocellular carcinoma, 
HGS-OvCa - high-gradeserous ovarian carcinoma.
d, LOH (loss of heterozygosity) was defined as 0 allelic copies. Amplification was defined 
as > 1allelic copy for samples with 0 genome doublings, and as > 2 allelic copies for those 
with 1genome doubling. Calls were made based on the modal allelic copy numbers of 
eachchromosome arm. Dashed lines indicate y=x.
e, SCNAs, defined as regions differing from the modal absolute copy number of each 
sample,were binned at adaptive resolution to maintain 200 SCNAs per bin, and 
renormalized by binlength. The value in each bin was further divided by the number of 
tumor samples in eachgenome doubling class, indicated by color as in a. The black line 
indicates slope = −1. Linearregression models were fit independently for each class using 
SCNAs 0.5 < x < 20 Mb. Thisresulted in fitted slope values of -1.05, -0.96, and -0.88 for 0, 
1, and > 1 genome doublings,respectively (not shown).
Carter et al. Page 33
Nat Biotechnol. Author manuscript; available in PMC 2015 April 02.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 7. Genetic and clinical associations with genome doubling in primary HGS-OvCa samples
a-e, Colors correspond to putative genome doubling status, as indicated. Significance codes: 
**– P < 10-5, * – P < 0.05, NS – P > 0.05.
a-c, Number of mutations in indicated classes as a function of genome doublings. P-values 
were calculated with the two-sided Wilcoxin rank-sum test comparing samples with 0 and 1 
genome doublings. Error bars indicate standard errors of the means.
d, P-values were calculated with the two-sided Wilcoxin rank-sum test.
e, P-values were calculated using the log-rank test.
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